MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Markian Pryshliak - , Technical University of Berlin (Author)
  • Ahmet Hazini - , Technical University of Berlin (Author)
  • Klaus Knoch - , Molecular Diabetology, TUD Dresden University of Technology (Author)
  • Babette Dieringer - , Technical University of Berlin (Author)
  • Beatrice Tolksdorf - , Technical University of Berlin (Author)
  • Michele Solimena - , Molecular Diabetology, TUD Dresden University of Technology (Author)
  • Jens Kurreck - , Technical University of Berlin (Author)
  • Sandra Pinkert - , Free University of Berlin (Author)
  • Henry Fechner - , Technical University of Berlin (Author)

Abstract

Coxsackievirus B3 (CVB3) has potential as a new oncolytic agent for the treatment of cancer but can induce severe pancreatitis. Here, we inserted target sequences of the microRNA miR-375 (miR-375TS) into the 5′ terminus of the polyprotein encoding sequence or into the 3′UTR of the CVB3 strain rCVB3.1 to prevent viral replication in the pancreas. In pancreatic EndoC-βH1 cells expressing miR-375 endogenously, replication of the 5′-miR-375TS virus and that of the 3′-miR-375TS virus was reduced by 4 × 103-fold and 3.9 × 104-fold, respectively, compared to the parental rCVB3.1. In colorectal carcinoma cells, replication and cytotoxicity of both viruses were slightly reduced compared to rCVB3.1, but less pronounced for the 3′-miR-375TS virus. Thus, CVB3 with miR-375TS in the 3′UTR of the viral genome may be suitable to avoid pancreatic toxicity.

Details

Original languageEnglish
Pages (from-to)763-775
Number of pages13
JournalFEBS letters
Volume594
Issue number4
Publication statusPublished - 1 Feb 2020
Peer-reviewedYes

External IDs

PubMed 31643074

Keywords

Sustainable Development Goals

Keywords

  • cancer therapy, colorectal cancer, coxsackievirus B3, microRNA, oncolytic virus